NIFTY 50

Decoding the US drug regulator’s actions on pharma plants

Does the issue of multiple observations to a plant site by the US drug regulator USFDA mean it will get a Warning Letter? Why is it that some companies that are issued just a few observations get Import Alerts? Why do some companies take years to solve USFDA regulatory problems? Does India face a ‘culture’ problem when it comes to lack of compliance? Amit Rajan, an expert on quality and compliance issues, answers these  and many more questions on a critical part of the operations of pharma companies in this  week’s podcast. He breaks down the basics of Form 483s, EIRs and the FDA. Tune in!

Sign Up For Primo, Our Free Daily Newsletter